Pub Date : 2024-12-01Epub Date: 2024-06-04DOI: 10.1016/j.euf.2024.05.019
Maria Giovanna Asmundo, Emil Durukan, Giorgio Ivan Russo, Christian Fuglesang S Jensen, Peter Busch Østergren, Sebastiano Cimino, Mikkel Fode
Background and objective: It is considered standard for authors of scientific papers to provide access to their raw data. The purpose of this study was to investigate data availability statements (DAS) and the actual availability of data in urology.
Methods: The DAS policies of the top ten urology journals were retrieved. Then 190 selected papers were classified according to their DAS status. Finally, we contacted the corresponding authors of papers that stated that data were available on request to enquire about this possibility.
Key findings and limitations: All journals either required or highly recommended a DAS. Among the selected articles, 52% (99/190) included a DAS stating data availability, most often on reasonable request to the corresponding author. A formal DAS was lacking in 29.5% (56/190) of the articles, with an additional 18.3% (35/190) citing various reasons for data unavailability. On contact, 23.4% (15/64) of corresponding authors indicated a willingness to share their data. Overall, data were unavailable in 73.7% (140/190) of cases. There was no difference between papers dealing with malignant and benign diseases.
Conclusions and clinical implications: There is a gap between the intention to share data and actual practice in major urological journals. As data sharing plays a critical role in safeguarding the reliability of published results and in the potential for reanalysis and merging of datasets, there is a clear need for improvement. Easier access to data repositories and stronger enforcement of existing journal policies are essential.
Patient summary: To ensure the reliability of data and allow further analyses, major urology journals require authors to make their data available to other researchers when possible. However, in practice we found that data were only accessible for about a quarter of published scientific papers.
背景和目的:科学论文的作者提供原始数据是一项标准要求。本研究旨在调查数据可用性声明(DAS)和泌尿科数据的实际可用性:方法:检索了排名前十的泌尿学期刊的 DAS 政策。方法:我们检索了排名前十的泌尿外科期刊的数据可用性声明(DAS)政策,然后根据其 DAS 状态对 190 篇选定论文进行了分类。最后,我们联系了声明可应要求提供数据的论文的通讯作者,询问这种可能性:所有期刊都要求或强烈推荐DAS。在所选文章中,52%(99/190)的文章包含了DAS,说明了数据的可用性,最常见的情况是向通讯作者提出合理要求。29.5%(56/190)的文章未提供正式的 DAS,另有 18.3%(35/190)的文章以各种理由说明数据不可用。经联系,23.4%(15/64)的通讯作者表示愿意共享数据。总体而言,73.7%(140/190)的论文无法提供数据。涉及恶性和良性疾病的论文之间没有差异:结论与临床意义:主要泌尿外科期刊共享数据的意愿与实际做法之间存在差距。由于数据共享在保障发表结果的可靠性以及重新分析和合并数据集的可能性方面发挥着至关重要的作用,因此显然有必要加以改进。患者摘要:为了确保数据的可靠性并允许进一步分析,主要泌尿学期刊要求作者在可能的情况下向其他研究人员提供数据。然而,在实践中,我们发现仅有约四分之一的已发表科学论文可以获取数据。
{"title":"Data Availability Statements and Data Sharing in Urology: A False Promise?","authors":"Maria Giovanna Asmundo, Emil Durukan, Giorgio Ivan Russo, Christian Fuglesang S Jensen, Peter Busch Østergren, Sebastiano Cimino, Mikkel Fode","doi":"10.1016/j.euf.2024.05.019","DOIUrl":"10.1016/j.euf.2024.05.019","url":null,"abstract":"<p><strong>Background and objective: </strong>It is considered standard for authors of scientific papers to provide access to their raw data. The purpose of this study was to investigate data availability statements (DAS) and the actual availability of data in urology.</p><p><strong>Methods: </strong>The DAS policies of the top ten urology journals were retrieved. Then 190 selected papers were classified according to their DAS status. Finally, we contacted the corresponding authors of papers that stated that data were available on request to enquire about this possibility.</p><p><strong>Key findings and limitations: </strong>All journals either required or highly recommended a DAS. Among the selected articles, 52% (99/190) included a DAS stating data availability, most often on reasonable request to the corresponding author. A formal DAS was lacking in 29.5% (56/190) of the articles, with an additional 18.3% (35/190) citing various reasons for data unavailability. On contact, 23.4% (15/64) of corresponding authors indicated a willingness to share their data. Overall, data were unavailable in 73.7% (140/190) of cases. There was no difference between papers dealing with malignant and benign diseases.</p><p><strong>Conclusions and clinical implications: </strong>There is a gap between the intention to share data and actual practice in major urological journals. As data sharing plays a critical role in safeguarding the reliability of published results and in the potential for reanalysis and merging of datasets, there is a clear need for improvement. Easier access to data repositories and stronger enforcement of existing journal policies are essential.</p><p><strong>Patient summary: </strong>To ensure the reliability of data and allow further analyses, major urology journals require authors to make their data available to other researchers when possible. However, in practice we found that data were only accessible for about a quarter of published scientific papers.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"999-1002"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-06-15DOI: 10.1016/j.euf.2024.06.002
Riccardo Mastroianni, Giuseppe Chiacchio, Giuseppe Simone
{"title":"Reply to Wei He, Shuxiong Zeng, and Chuanliang Xu's Letter to the Editor re: Riccardo Mastroianni, Gabriele Tuderti, Mariaconsiglia Ferriero, et al. Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial. Eur Urol 2024;85:422-30.","authors":"Riccardo Mastroianni, Giuseppe Chiacchio, Giuseppe Simone","doi":"10.1016/j.euf.2024.06.002","DOIUrl":"10.1016/j.euf.2024.06.002","url":null,"abstract":"","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"1068-1069"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-06-21DOI: 10.1016/j.euf.2024.06.004
Sinan Khadhouri, Artsiom Hramyka, Kevin Gallagher, Alexander Light, Simona Ippoliti, Marie Edison, Cameron Alexander, Meghana Kulkarni, Eleanor Zimmermann, Arjun Nathan, Luca Orecchia, Ravi Banthia, Pietro Piazza, David Mak, Nikolaos Pyrgidis, Prabhat Narayan, Pablo Abad Lopez, Faisal Nawaz, Trung-Thanh Tran, Francesco Claps, Donnacha Hogan, Juan Gomez Rivas, Santiago Alonso, Ijeoma Chibuzo, Beatriz Gutierrez Hidalgo, Jessica Whitburn, Jeremy Teoh, Gautier Marcq, Alexandra Szostek, Jasper Bondad, Petros Sountoulides, Tom Kelsey, Veeru Kasivisvanathan
Background: The IDENTIFY study developed a model to predict urinary tract cancer using patient characteristics from a large multicentre, international cohort of patients referred with haematuria. In addition to calculating an individual's cancer risk, it proposes thresholds to stratify them into very-low-risk (<1%), low-risk (1-<5%), intermediate-risk (5-<20%), and high-risk (≥20%) groups.
Objective: To externally validate the IDENTIFY haematuria risk calculator and compare traditional regression with machine learning algorithms.
Design, setting, and participants: Prospective data were collected on patients referred to secondary care with new haematuria. Data were collected for patient variables included in the IDENTIFY risk calculator, cancer outcome, and TNM staging. Machine learning methods were used to evaluate whether better models than those developed with traditional regression methods existed.
Outcome measurements and statistical analysis: The area under the receiver operating characteristic curve (AUC) for the detection of urinary tract cancer, calibration coefficient, calibration in the large (CITL), and Brier score were determined.
Results and limitations: There were 3582 patients in the validation cohort. The development and validation cohorts were well matched. The AUC of the IDENTIFY risk calculator on the validation cohort was 0.78. This improved to 0.80 on a subanalysis of urothelial cancer prevalent countries alone, with a calibration slope of 1.04, CITL of 0.24, and Brier score of 0.14. The best machine learning model was Random Forest, which achieved an AUC of 0.76 on the validation cohort. There were no cancers stratified to the very-low-risk group in the validation cohort. Most cancers were stratified to the intermediate- and high-risk groups, with more aggressive cancers in higher-risk groups.
Conclusions: The IDENTIFY risk calculator performed well at predicting cancer in patients referred with haematuria on external validation. This tool can be used by urologists to better counsel patients on their cancer risks, to prioritise diagnostic resources on appropriate patients, and to avoid unnecessary invasive procedures in those with a very low risk of cancer.
Patient summary: We previously developed a calculator that predicts patients' risk of cancer when they have blood in their urine, based on their personal characteristics. We have validated this risk calculator, by testing it on a separate group of patients to ensure that it works as expected. Most patients found to have cancer tended to be in the higher-risk groups and had more aggressive types of cancer with a higher risk. This tool can be used by clinicians to fast-track high-risk patients based on the calculator and investigate them more thoroughly.
{"title":"Machine Learning and External Validation of the IDENTIFY Risk Calculator for Patients with Haematuria Referred to Secondary Care for Suspected Urinary Tract Cancer.","authors":"Sinan Khadhouri, Artsiom Hramyka, Kevin Gallagher, Alexander Light, Simona Ippoliti, Marie Edison, Cameron Alexander, Meghana Kulkarni, Eleanor Zimmermann, Arjun Nathan, Luca Orecchia, Ravi Banthia, Pietro Piazza, David Mak, Nikolaos Pyrgidis, Prabhat Narayan, Pablo Abad Lopez, Faisal Nawaz, Trung-Thanh Tran, Francesco Claps, Donnacha Hogan, Juan Gomez Rivas, Santiago Alonso, Ijeoma Chibuzo, Beatriz Gutierrez Hidalgo, Jessica Whitburn, Jeremy Teoh, Gautier Marcq, Alexandra Szostek, Jasper Bondad, Petros Sountoulides, Tom Kelsey, Veeru Kasivisvanathan","doi":"10.1016/j.euf.2024.06.004","DOIUrl":"10.1016/j.euf.2024.06.004","url":null,"abstract":"<p><strong>Background: </strong>The IDENTIFY study developed a model to predict urinary tract cancer using patient characteristics from a large multicentre, international cohort of patients referred with haematuria. In addition to calculating an individual's cancer risk, it proposes thresholds to stratify them into very-low-risk (<1%), low-risk (1-<5%), intermediate-risk (5-<20%), and high-risk (≥20%) groups.</p><p><strong>Objective: </strong>To externally validate the IDENTIFY haematuria risk calculator and compare traditional regression with machine learning algorithms.</p><p><strong>Design, setting, and participants: </strong>Prospective data were collected on patients referred to secondary care with new haematuria. Data were collected for patient variables included in the IDENTIFY risk calculator, cancer outcome, and TNM staging. Machine learning methods were used to evaluate whether better models than those developed with traditional regression methods existed.</p><p><strong>Outcome measurements and statistical analysis: </strong>The area under the receiver operating characteristic curve (AUC) for the detection of urinary tract cancer, calibration coefficient, calibration in the large (CITL), and Brier score were determined.</p><p><strong>Results and limitations: </strong>There were 3582 patients in the validation cohort. The development and validation cohorts were well matched. The AUC of the IDENTIFY risk calculator on the validation cohort was 0.78. This improved to 0.80 on a subanalysis of urothelial cancer prevalent countries alone, with a calibration slope of 1.04, CITL of 0.24, and Brier score of 0.14. The best machine learning model was Random Forest, which achieved an AUC of 0.76 on the validation cohort. There were no cancers stratified to the very-low-risk group in the validation cohort. Most cancers were stratified to the intermediate- and high-risk groups, with more aggressive cancers in higher-risk groups.</p><p><strong>Conclusions: </strong>The IDENTIFY risk calculator performed well at predicting cancer in patients referred with haematuria on external validation. This tool can be used by urologists to better counsel patients on their cancer risks, to prioritise diagnostic resources on appropriate patients, and to avoid unnecessary invasive procedures in those with a very low risk of cancer.</p><p><strong>Patient summary: </strong>We previously developed a calculator that predicts patients' risk of cancer when they have blood in their urine, based on their personal characteristics. We have validated this risk calculator, by testing it on a separate group of patients to ensure that it works as expected. Most patients found to have cancer tended to be in the higher-risk groups and had more aggressive types of cancer with a higher risk. This tool can be used by clinicians to fast-track high-risk patients based on the calculator and investigate them more thoroughly.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"1034-1042"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-07-23DOI: 10.1016/j.euf.2024.06.012
Severin Rodler, Serena Maruccia, Andre Abreu, Declan Murphy, David Canes, Stacy Loeb, Rena D Malik, Aditya Bagrodia, Giovanni E Cacciamani
Background and objective: Readability of patient education materials is of utmost importance to ensure understandability and dissemination of health care information in uro-oncology. We aimed to investigate the readability of the official patient education materials of the European Association of Urology (EAU) and American Urology Association (AUA).
Methods: Patient education materials for prostate, bladder, kidney, testicular, penile, and urethral cancers were retrieved from the respective organizations. Readability was assessed via the WebFX online tool for Flesch Kincaid Reading Ease Score (FRES) and for reading grade levels by Flesch Kincaid Grade Level (FKGL), Gunning Fog Score (GFS), Smog Index (SI), Coleman Liau Index (CLI), and Automated Readability Index (ARI). Layperson readability was defined as a FRES of ≥70 and with the other readability indexes <7 according to European Union recommendations. This study assessed only objective readability and no other metrics such as understandability.
Key findings and limitations: Most patient education materials failed to meet the recommended threshold for laypersons. The mean readability for EAU patient education material was as follows: FRES 50.9 (standard error [SE]: 3.0), and FKGL, GFS, SI, CLI, and ARI all with scores ≥7. The mean readability for AUA patient material was as follows: FRES 64.0 (SE: 1.4), with all of FKGL, GFS, SI, and ARI scoring ≥7 readability. Only 13 out of 70 (18.6%) patient education materials' paragraphs met the readability requirements. The mean readability for bladder cancer patient education materials was the lowest, with a FRES of 36.7 (SE: 4.1).
Conclusions and clinical implications: Patient education materials from leading urological associations reveal readability levels beyond the recommended thresholds for laypersons and may not be understood easily by patients. There is a future need for more patient-friendly reading materials.
Patient summary: This study checked whether health information about different cancers was easy to read. Most of it was too hard for patients to understand.
{"title":"Readability Assessment of Patient Education Materials on Uro-oncological Diseases Using Automated Measures.","authors":"Severin Rodler, Serena Maruccia, Andre Abreu, Declan Murphy, David Canes, Stacy Loeb, Rena D Malik, Aditya Bagrodia, Giovanni E Cacciamani","doi":"10.1016/j.euf.2024.06.012","DOIUrl":"10.1016/j.euf.2024.06.012","url":null,"abstract":"<p><strong>Background and objective: </strong>Readability of patient education materials is of utmost importance to ensure understandability and dissemination of health care information in uro-oncology. We aimed to investigate the readability of the official patient education materials of the European Association of Urology (EAU) and American Urology Association (AUA).</p><p><strong>Methods: </strong>Patient education materials for prostate, bladder, kidney, testicular, penile, and urethral cancers were retrieved from the respective organizations. Readability was assessed via the WebFX online tool for Flesch Kincaid Reading Ease Score (FRES) and for reading grade levels by Flesch Kincaid Grade Level (FKGL), Gunning Fog Score (GFS), Smog Index (SI), Coleman Liau Index (CLI), and Automated Readability Index (ARI). Layperson readability was defined as a FRES of ≥70 and with the other readability indexes <7 according to European Union recommendations. This study assessed only objective readability and no other metrics such as understandability.</p><p><strong>Key findings and limitations: </strong>Most patient education materials failed to meet the recommended threshold for laypersons. The mean readability for EAU patient education material was as follows: FRES 50.9 (standard error [SE]: 3.0), and FKGL, GFS, SI, CLI, and ARI all with scores ≥7. The mean readability for AUA patient material was as follows: FRES 64.0 (SE: 1.4), with all of FKGL, GFS, SI, and ARI scoring ≥7 readability. Only 13 out of 70 (18.6%) patient education materials' paragraphs met the readability requirements. The mean readability for bladder cancer patient education materials was the lowest, with a FRES of 36.7 (SE: 4.1).</p><p><strong>Conclusions and clinical implications: </strong>Patient education materials from leading urological associations reveal readability levels beyond the recommended thresholds for laypersons and may not be understood easily by patients. There is a future need for more patient-friendly reading materials.</p><p><strong>Patient summary: </strong>This study checked whether health information about different cancers was easy to read. Most of it was too hard for patients to understand.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"1055-1061"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-07-14DOI: 10.1016/j.euf.2024.06.013
David-Dan Nguyen, Naeem Bhojani, Quoc-Dien Trinh
{"title":"Re: Alessandro Uleri, Jean Nicolas Cornu, Andrea Gobbo, et al. Association of 5α-Reductase Inhibitors with Depression and Suicide: A Mini Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.04.009.","authors":"David-Dan Nguyen, Naeem Bhojani, Quoc-Dien Trinh","doi":"10.1016/j.euf.2024.06.013","DOIUrl":"10.1016/j.euf.2024.06.013","url":null,"abstract":"","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"1066-1067"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2025-01-13DOI: 10.1016/j.euf.2024.12.007
Ilaha Isali, Thomas R Wong, Shari Tian
Microbiome research has the potential to provide valuable information regarding the complex relationship between microbial communities and the human body. To help facilitate the translation of this potentially revolutionary research to clinical medicine, common guidelines and best practices are necessary. These guidelines should be based on the key findings of recent research in the field and address the primary areas of discrepancy in the previously published literature. Based on this review's findings, future microbiome research should adopt a consistent and clear approach to nomenclature, using standardized terminology to mitigate confusion. Additionally, only sample collection methods proven to reduce the risk of contamination should be utilized. While sample storage often creates difficulty in microbiome research, there are proven techniques that can improve results. With the wide array of research methodologies in the literature, standardization of metadata collection, kits, and analysis software could also be beneficial. Finally, documentation and records are critical in ensuring reproducibility, as is the case with all basic research. This brief review provides a foundation for evidence-based guidelines in microbiome research. PATIENT SUMMARY: This report outlines general guidelines and best practices for conducting microbiome research, which could significantly advance the field of medicine.
{"title":"Best Practice Guidelines for Collecting Microbiome Samples in Research Studies.","authors":"Ilaha Isali, Thomas R Wong, Shari Tian","doi":"10.1016/j.euf.2024.12.007","DOIUrl":"10.1016/j.euf.2024.12.007","url":null,"abstract":"<p><p>Microbiome research has the potential to provide valuable information regarding the complex relationship between microbial communities and the human body. To help facilitate the translation of this potentially revolutionary research to clinical medicine, common guidelines and best practices are necessary. These guidelines should be based on the key findings of recent research in the field and address the primary areas of discrepancy in the previously published literature. Based on this review's findings, future microbiome research should adopt a consistent and clear approach to nomenclature, using standardized terminology to mitigate confusion. Additionally, only sample collection methods proven to reduce the risk of contamination should be utilized. While sample storage often creates difficulty in microbiome research, there are proven techniques that can improve results. With the wide array of research methodologies in the literature, standardization of metadata collection, kits, and analysis software could also be beneficial. Finally, documentation and records are critical in ensuring reproducibility, as is the case with all basic research. This brief review provides a foundation for evidence-based guidelines in microbiome research. PATIENT SUMMARY: This report outlines general guidelines and best practices for conducting microbiome research, which could significantly advance the field of medicine.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"909-913"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2025-01-17DOI: 10.1016/j.euf.2024.12.005
Ceejay N Saenz, Michael L Neugent, Nicole J De Nisco
After identifying a urinary microbiota, new insights have emerged into how urinary tract infections (UTIs) develop and recur in women. This review explores factors influencing the urinary microbiome, and its role in UTI susceptibility and recurrence. Age, menopausal status, estrogen, and prior UTIs can impact the urinary microbiome significantly, with estrogen promoting predominance of beneficial Lactobacillus species in women. Study of the urinary microbiome has identified anaerobic bacteria as emerging uropathogens, as well as microbiome species that are markers of recurrent UTI susceptibility. UTIs also impact microbiome functions, including disrupting microbiome scaffolding sites (ie, glycosaminoglycans) and enriching antibiotic resistance genes. A clear link is becoming established between the natural flora of the human urinary tract and UTI susceptibility, which is also impacted by aging and the menopausal transition. Deepening this understanding can lead to the development of a new generation of UTI therapeutic and preventative strategies aimed at modulating the urinary microbiome. PATIENT SUMMARY: A clear link is becoming established between the natural flora of the human urinary tract and urinary tract infection (UTI) susceptibility, which is also impacted by aging and the menopausal transition. Deepening this understanding can lead to the development of a new generation of UTI therapeutic and preventative strategies aimed at modulating the urinary microbiome.
{"title":"The Human Urinary Microbiome and Its Potential Role in Urinary Tract Infections.","authors":"Ceejay N Saenz, Michael L Neugent, Nicole J De Nisco","doi":"10.1016/j.euf.2024.12.005","DOIUrl":"10.1016/j.euf.2024.12.005","url":null,"abstract":"<p><p>After identifying a urinary microbiota, new insights have emerged into how urinary tract infections (UTIs) develop and recur in women. This review explores factors influencing the urinary microbiome, and its role in UTI susceptibility and recurrence. Age, menopausal status, estrogen, and prior UTIs can impact the urinary microbiome significantly, with estrogen promoting predominance of beneficial Lactobacillus species in women. Study of the urinary microbiome has identified anaerobic bacteria as emerging uropathogens, as well as microbiome species that are markers of recurrent UTI susceptibility. UTIs also impact microbiome functions, including disrupting microbiome scaffolding sites (ie, glycosaminoglycans) and enriching antibiotic resistance genes. A clear link is becoming established between the natural flora of the human urinary tract and UTI susceptibility, which is also impacted by aging and the menopausal transition. Deepening this understanding can lead to the development of a new generation of UTI therapeutic and preventative strategies aimed at modulating the urinary microbiome. PATIENT SUMMARY: A clear link is becoming established between the natural flora of the human urinary tract and urinary tract infection (UTI) susceptibility, which is also impacted by aging and the menopausal transition. Deepening this understanding can lead to the development of a new generation of UTI therapeutic and preventative strategies aimed at modulating the urinary microbiome.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"889-892"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-12-10DOI: 10.1016/j.euf.2024.11.010
Jose Agudelo, Sromona Mukherjee, Mangesh Suryavanshi, Bernardita Ljubetic, Marcelo Mass Lindenbaum, Aaron W Miller
Nephrolithiasis imposes a significant health care burden around the world. In the past decade, there has been considerable interest in the human microbiota in relation to the onset of nephrolithiasis. Most of the research has focused on degradation of oxalate, a known causative factor for nephrolithiasis, by bacteria in the gut. More recently, the role of antibiotic exposure and changes to short-chain fatty acids have been investigated. Studies have revealed that the urinary tract, previously thought to be sterile, harbors resident microbial communities closely associated with nephrolithiasis. In this mini-review, we evaluate potential causative roles of the microbiome in the onset of nephrolithiasis and the development of novel therapies to prevent this disease. PATIENT SUMMARY: This mini-review discusses scientific evidence on the influence of bacteria in our intestines and urinary tract on the formation of kidney stones. We discuss possible therapies targeting these bacteria that could prevent kidney stones from forming.
{"title":"Mechanism of Nephrolithiasis: Does the Microbiome Play a Role?","authors":"Jose Agudelo, Sromona Mukherjee, Mangesh Suryavanshi, Bernardita Ljubetic, Marcelo Mass Lindenbaum, Aaron W Miller","doi":"10.1016/j.euf.2024.11.010","DOIUrl":"10.1016/j.euf.2024.11.010","url":null,"abstract":"<p><p>Nephrolithiasis imposes a significant health care burden around the world. In the past decade, there has been considerable interest in the human microbiota in relation to the onset of nephrolithiasis. Most of the research has focused on degradation of oxalate, a known causative factor for nephrolithiasis, by bacteria in the gut. More recently, the role of antibiotic exposure and changes to short-chain fatty acids have been investigated. Studies have revealed that the urinary tract, previously thought to be sterile, harbors resident microbial communities closely associated with nephrolithiasis. In this mini-review, we evaluate potential causative roles of the microbiome in the onset of nephrolithiasis and the development of novel therapies to prevent this disease. PATIENT SUMMARY: This mini-review discusses scientific evidence on the influence of bacteria in our intestines and urinary tract on the formation of kidney stones. We discuss possible therapies targeting these bacteria that could prevent kidney stones from forming.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"902-905"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-06-05DOI: 10.1016/j.euf.2024.05.009
Bruno Bucca, Luca M Gobbi, Orietta Dalpiaz, Vincenzo Asero, Carlo M Scornajenghi, Federico Alviani, Leslie Claire Licari, Eugenio Bologna, Christian Gozzi
Background and objective: Several minimally invasive treatments have been developed to treat benign prostatic obstruction (BPO) via a transurethral approach, with a non-negligible risk of complications such as urethral stricture and external sphincter damage. Our aim was to present the Gozzi surgical technique for suprapubic transvesical adenoma resection of the prostate (STAR-P) for BPO and to assess its safety, feasibility, and outcomes.
Methods: We conducted a retrospective analysis of 44 consecutive patients who underwent STAR-P for BPO. All the procedures were performed in a single private hospital by one surgeon from 2020 to 2022. An innovative resectoscope designed by the surgeon was subsequently produced by Tontarra Medizintechnik (Wurmlingen, Germany) with a 42.06 Fr external sheath that allows the use of loops of three different sizes. The instrument is inserted into the bladder via suprapubic access, which ensures greater freedom of movement without compromising the external sphincter. Clinical data were retrospectively collected. Preoperative and intraoperative variables, postoperative complications, and functional outcomes of the STAR-P procedure were assessed. A descriptive statistical analysis was performed.
Key findings and limitations: No intraoperative complications were observed. Two patients (4.5%) experienced urinary urgency symptoms after catheter removal that resolved within 90 d. Median times were 105 min for surgery overall and 65 min for resection. All patients showed an improvement in voiding quality.
Conclusions and clinical implications: STAR-P is a safe, feasible, and cost-effective procedure that spares the bulbomembranous and penile urethra and the external urethral sphincter, and should be discussed with patients as a possible option for treatment of BPO.
Patient summary: We describe a new, safe, and feasible technique for surgical treatment of urinary obstruction caused by a large prostate. Keyhole surgery is performed through the lower abdomen, which means that the urethra below the prostate is not damaged. Only a small scar of 2-3 cm in the lower abdomen is evident at the end of the healing process.
{"title":"Suprapubic Transvesical Adenoma Resection of the Prostate (STAR-P): A Novel Technique for Surgical Treatment of Benign Prostatic Hyperplasia.","authors":"Bruno Bucca, Luca M Gobbi, Orietta Dalpiaz, Vincenzo Asero, Carlo M Scornajenghi, Federico Alviani, Leslie Claire Licari, Eugenio Bologna, Christian Gozzi","doi":"10.1016/j.euf.2024.05.009","DOIUrl":"10.1016/j.euf.2024.05.009","url":null,"abstract":"<p><strong>Background and objective: </strong>Several minimally invasive treatments have been developed to treat benign prostatic obstruction (BPO) via a transurethral approach, with a non-negligible risk of complications such as urethral stricture and external sphincter damage. Our aim was to present the Gozzi surgical technique for suprapubic transvesical adenoma resection of the prostate (STAR-P) for BPO and to assess its safety, feasibility, and outcomes.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 44 consecutive patients who underwent STAR-P for BPO. All the procedures were performed in a single private hospital by one surgeon from 2020 to 2022. An innovative resectoscope designed by the surgeon was subsequently produced by Tontarra Medizintechnik (Wurmlingen, Germany) with a 42.06 Fr external sheath that allows the use of loops of three different sizes. The instrument is inserted into the bladder via suprapubic access, which ensures greater freedom of movement without compromising the external sphincter. Clinical data were retrospectively collected. Preoperative and intraoperative variables, postoperative complications, and functional outcomes of the STAR-P procedure were assessed. A descriptive statistical analysis was performed.</p><p><strong>Key findings and limitations: </strong>No intraoperative complications were observed. Two patients (4.5%) experienced urinary urgency symptoms after catheter removal that resolved within 90 d. Median times were 105 min for surgery overall and 65 min for resection. All patients showed an improvement in voiding quality.</p><p><strong>Conclusions and clinical implications: </strong>STAR-P is a safe, feasible, and cost-effective procedure that spares the bulbomembranous and penile urethra and the external urethral sphincter, and should be discussed with patients as a possible option for treatment of BPO.</p><p><strong>Patient summary: </strong>We describe a new, safe, and feasible technique for surgical treatment of urinary obstruction caused by a large prostate. Keyhole surgery is performed through the lower abdomen, which means that the urethra below the prostate is not damaged. Only a small scar of 2-3 cm in the lower abdomen is evident at the end of the healing process.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":"991-998"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141260239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}